Haematology Rapid Tests & Point of Care (POC) - Medical Devices Pipeline Assessment, 2017

Publisher Name :
Date: 01-Aug-2017
No. of pages: 131

Haematology Rapid Tests & Point of Care (POC) - Medical Devices Pipeline Assessment, 2017

Summary

GlobalData's Medical Devices sector report, "Haematology Rapid Tests & Point of Care (POC) - Medical Devices Pipeline Assessment, 2017" provides an overview of Haematology Rapid Tests & Point of Care (POC) currently in pipeline stage.

The report provides comprehensive information on the pipeline products with comparative analysis of the products at various stages of development. The report reviews major players involved in the pipeline product development. It also provides information about clinical trials in progress, which includes trial phase, trial status, trial start and end dates, and, the number of trials for the key Haematology Rapid Tests & Point of Care (POC) pipeline products.

This report is prepared using data sourced from in-house databases, secondary and primary research by GlobalData's team of industry experts.

*Note: Certain sections in the report may be removed or altered based on the availability and relevance of data in relation to the equipment type.

Scope

- Extensive coverage of the Haematology Rapid Tests & Point of Care (POC) under development

- The report reviews details of major pipeline products which includes, product description, licensing and collaboration details and other developmental activities

- The report reviews the major players involved in the development of Haematology Rapid Tests & Point of Care (POC) and list all their pipeline projects

- The coverage of pipeline products based on various stages of development ranging from Early Development to Approved / Issued stage

- The report provides key clinical trial data of ongoing trials specific to pipeline products

- Recent developments in the segment / industry

Reasons to buy

The report enables you to -

- Formulate significant competitor information, analysis, and insights to improve R&D strategies

- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

- Identify and understand important and diverse types of Haematology Rapid Tests & Point of Care (POC) under development

- Develop market-entry and market expansion strategies

- Plan mergers and acquisitions effectively by identifying major players with the most promising pipeline

- In-depth analysis of the product's current stage of development, territory and estimated launch date

Haematology Rapid Tests & Point of Care (POC) - Medical Devices Pipeline Assessment, 2017

1 Table of Contents
1 Table of Contents 2
1.1 List of Tables 5
1.2 List of Figures 6
2 Introduction 7
2.1 Haematology Rapid Tests & Point of Care (POC) Overview 7
3 Products under Development 8
3.1 Haematology Rapid Tests & Point of Care (POC) - Pipeline Products by Stage of Development 8
3.2 Haematology Rapid Tests & Point of Care (POC) - Pipeline Products by Segment 9
3.3 Haematology Rapid Tests & Point of Care (POC) - Pipeline Products by Territory 10
3.4 Haematology Rapid Tests & Point of Care (POC) - Pipeline Products by Regulatory Path 11
3.5 Haematology Rapid Tests & Point of Care (POC) - Pipeline Products by Estimated Approval Date 12
4 Haematology Rapid Tests & Point of Care (POC) - Pipeline Products under Development by Companies 13
4.1 Haematology Rapid Tests & Point of Care (POC) Companies - Pipeline Products by Stage of Development 13
4.2 Haematology Rapid Tests & Point of Care (POC) - Pipeline Products by Stage of Development 14
5 Haematology Rapid Tests & Point of Care (POC) Companies and Product Overview 16
5.1 Atomo Diagnostics Pty Limited Company Overview 16
5.1.1 Atomo Diagnostics Pty Limited Pipeline Products & Ongoing Clinical Trials Overview 16
5.2 BioMedomics Inc Company Overview 17
5.2.1 BioMedomics Inc Pipeline Products & Ongoing Clinical Trials Overview 17
5.3 Biosurfit, SA Company Overview 18
5.3.1 Biosurfit, SA Pipeline Products & Ongoing Clinical Trials Overview 18
5.4 Carclo Diagnostic Solutions Ltd Company Overview 20
5.4.1 Carclo Diagnostic Solutions Ltd Pipeline Products & Ongoing Clinical Trials Overview 20
5.5 Cascade Metrix, Inc. Company Overview 21
5.5.1 Cascade Metrix, Inc. Pipeline Products & Ongoing Clinical Trials Overview 21
5.6 Correlia Biosystems, Inc. Company Overview 22
5.6.1 Correlia Biosystems, Inc. Pipeline Products & Ongoing Clinical Trials Overview 22
5.7 EKF Diagnostics Holdings Plc Company Overview 23
5.7.1 EKF Diagnostics Holdings Plc Pipeline Products & Ongoing Clinical Trials Overview 23
5.8 Emosis SAS Company Overview 24
5.8.1 Emosis SAS Pipeline Products & Ongoing Clinical Trials Overview 24
5.9 ET Healthcare, Inc. Company Overview 25
5.9.1 ET Healthcare, Inc. Pipeline Products & Ongoing Clinical Trials Overview 25
5.10 genedrive plc Company Overview 26
5.10.1 genedrive plc Pipeline Products & Ongoing Clinical Trials Overview 26
5.11 Helena Laboratories Corp. Company Overview 27
5.11.1 Helena Laboratories Corp. Pipeline Products & Ongoing Clinical Trials Overview 27
5.12 KeenCAT Technologies Company Overview 34
5.12.1 KeenCAT Technologies Pipeline Products & Ongoing Clinical Trials Overview 34
5.13 Ohio State University Company Overview 35
5.13.1 Ohio State University Pipeline Products & Ongoing Clinical Trials Overview 35
5.14 PortaScience Inc Company Overview 36
5.14.1 PortaScience Inc Pipeline Products & Ongoing Clinical Trials Overview 36
5.15 Sanguina LLC Company Overview 37
5.15.1 Sanguina LLC Pipeline Products & Ongoing Clinical Trials Overview 37
5.16 Siemens Healthcare GmbH Company Overview 38
5.16.1 Siemens Healthcare GmbH Pipeline Products & Ongoing Clinical Trials Overview 38
5.17 T2 Biosystems Inc Company Overview 44
5.17.1 T2 Biosystems Inc Pipeline Products & Ongoing Clinical Trials Overview 44
5.18 The University of Melbourne Company Overview 46
5.18.1 The University of Melbourne Pipeline Products & Ongoing Clinical Trials Overview 46
5.19 Universal Biosensors Inc Company Overview 47
5.19.1 Universal Biosensors Inc Pipeline Products & Ongoing Clinical Trials Overview 47
6 Haematology Rapid Tests & Point of Care (POC)- Recent Developments 48
6.1 Jun 15, 2017: Consort Medical: Full year results 48
6.2 Jun 14, 2017: Alere Reports First Quarter 2017 Financial Results 48
6.3 Jun 05, 2017: Alere Files Form 10-K, Reports Fourth Quarter and Full Year 2016 Financial Results 49
6.4 May 22, 2017: Alere Provides Preliminary Unaudited Financial Results 50
6.5 May 19, 2017: Henry Ford Health System to Present Webinar on T2MR 50
6.6 May 17, 2017: FDA warns Americans about risk of inaccurate results from certain lead tests 51
6.7 May 16, 2017: Akers Biosciences Announces Q1 2017 Earnings 52
6.8 May 04, 2017: Lea Paloheimo appointed Biohit Oyj's R&D and production director 53
6.9 May 04, 2017: Bio-Rad Reports First-Quarter 2017 Financial Results 54
6.10 Apr 27, 2017: Abaxis Reports Financial Performance for the Fourth Quarter and Fiscal 2017 and Declares Quarterly Cash Dividend 55
6.11 Apr 24, 2017: Quidel Reports First Quarter 2017 Financial Results 56
6.12 Apr 11, 2017: Akers Bioscience: Financial Results for the Year Ended December 31, 2016 57
6.13 Apr 11, 2017: Akers Biosciences Reports Earnings for Fiscal Year 2016 58
6.14 Apr 10, 2017: Akers Biosciences to Commercialize Heparin PF4 Rapid Test in Puerto Rico 62
6.15 Mar 30, 2017: Akers Biosciences Reports Preliminary Unaudited Earnings Highlights for Fiscal Year 2016 63
6.16 Mar 29, 2017: Sysmex America Announces Leadership Promotions 64
6.17 Mar 28, 2017: EMOSIS Announces the Opening of a Subsidiary in Israel 65
6.18 Mar 27, 2017: EMOSIS announces the appointment of Nicolas Rufin as Head of marketing and sales 65
6.19 Mar 26, 2017: Emosis Announces The Appointment Of Aurore Andre As Emosis CEO 66
6.20 Mar 20, 2017: EKF Diagnostics Holdings: Final results 66
6.21 Mar 13, 2017: Bio-Rad Intends to Propose Three New Independent Directors 67
6.22 Mar 13, 2017: Bio-Rad Initiates Long Term Financial Guidance; Commits to Defining Long Term Capital Allocation Targets and Hosting an Annual Investor Day 68
6.23 Mar 09, 2017: Alere Provides Update on Arriva Medical 69
6.24 Feb 23, 2017: VBio-Rad Reports Fourth-Quarter and Full-Year 2016 Financial Results 69
6.25 Feb 23, 2017: Bio-Rad Reports Fourth-Quarter and Full-Year 2016 Financial Results 71
6.26 Feb 20, 2017: Biohit Group Financial Statement Release 2016 73
6.27 Feb 20, 2017: Sysmex America to Distribute Erythrocyte Sedimentation Rate Products from Alifax 78
6.28 Feb 08, 2017: Quidel Reports Fourth Quarter and Full Year 2016 Financial Results 78
6.29 Feb 01, 2017: Akers Biosciences Announces Trading Update For The Twelve Months Ended December 31, 2016 80
6.30 Jan 26, 2017: Abaxis Reports Financial Performance for the Third Quarter of Fiscal 2017, Declares Quarterly Cash Dividend 81
6.31 Jan 23, 2017: Quidel Announces Modification of Revenue Reporting Categories 82
6.32 Jan 10, 2017: Abaxis Reports Preliminary Financial Performance For The Third Quarter Of Fiscal 2017 83
6.33 Jan 06, 2017: Quidel Announces Preliminary Revenue for Fourth Quarter 2016 83
6.34 Jan 04, 2017: Alere Laboratory Receives ABFT Accreditation 84
6.35 Jan 04, 2017: Alere Provides Update on Arriva Medical 84
6.36 Dec 28, 2016: Alere Provides Update on Arriva Medical 85
6.37 Dec 19, 2016: Akers Biosciences Announces 3-year Agreement with Greater New York Hospital Association for PIFA Heparin/Platelet Factor-4 Rapid Assay 85
6.38 Dec 19, 2016: Akers Biosciences Announces 3-year Agreement with Greater New York Hospital Association for PIFA PLUSS PF4 Rapid Assay 86
6.39 Dec 14, 2016: Beckman Coulter appoints IT Product Manager for Northern Europe 87
6.40 Dec 14, 2016: Siemens Healthineers to significantly expand its Walpole, Mass. Laboratory Diagnostic manufacturing facility 88
6.41 Dec 14, 2016: Consort Medical: Directorate Change 88
6.42 Dec 08, 2016: Khang & Khang Announces Securities Class Action Lawsuit against Alere and Reminds Investors with Losses to Contact the Firm 89
6.43 Dec 07, 2016: Abbott Seeks To Terminate Alere Acquisition 89
6.44 Dec 06, 2016: Consort Medical Reports Interim Results Results For The Six Months Ended 31 October 2016 89
6.45 Nov 25, 2016: Consort Medical: CFO Appointment 92
6.46 Nov 14, 2016: Akers Biosciences Announces Q3 Earnings 92
6.47 Nov 04, 2016: Alere Reports Third Quarter 2016 Financial Results 94
6.48 Nov 01, 2016: Bio-Rad Reports Third-Quarter Currency-Neutral Revenue Growth of 9.1 Percent 94
6.49 Oct 26, 2016: Quidel Reports Third Quarter 2016 Financial Results 95
6.50 Oct 25, 2016: Abaxis Reports Financial Performance For The Second Quarter Of Fiscal 2017 97
6.51 Oct 24, 2016: Study links small RNA molecule to pregnancy complication 98
6.52 Sep 12, 2016: EKF Diagnostics Holdings: Half-year Report 100
6.53 Sep 06, 2016: Alere Reports Second Quarter 2016 Financial Results 103
6.54 Sep 01, 2016: Blood test for new breast cancer subtype delays its progression 103
6.55 Aug 26, 2016: Ilari Patrakka appointed Biohit Oyj's Sales and Marketing Director 104
6.56 Aug 25, 2016: Alere Recalls INRatio and INRatio2 PT/INR Monitoring System Due to Incorrect Test Results 104
6.57 Aug 18, 2016: Frank Witney Joins RareCyte Board of Directors 106
6.58 Aug 18, 2016: Biohit Group Half Year Financial report 2016 106
6.59 Aug 17, 2016: Alere Reports First Quarter 2016 Financial Results 122
6.60 Aug 17, 2016: Consort Medical Announces Directorate Change 123
6.61 Aug 11, 2016: Akers Biosciences Announces H1 and Q2 2016 Earnings 123
6.62 Aug 08, 2016: Alere Files Form 10-K, Reports Fourth Quarter and Full Year 2015 Financial Results 125
6.63 Aug 03, 2016: Bio-Rad Reports Second-Quarter 2016 Financial Results 127
7 Appendix 128
7.1 Methodology 128
7.2 About GlobalData 131
7.3 Contact Us 131
7.4 Disclaimer 131

1.1 List of Tables
Table 1: Haematology Rapid Tests & Point of Care (POC) - Pipeline Products by Stage of Development 8
Table 2: Haematology Rapid Tests & Point of Care (POC) - Pipeline Products by Segment 9
Table 3: Haematology Rapid Tests & Point of Care (POC) - Pipeline Products by Territory 10
Table 4: Haematology Rapid Tests & Point of Care (POC) - Pipeline Products by Regulatory Path 11
Table 5: Haematology Rapid Tests & Point of Care (POC) - Pipeline Products by Estimated Approval Date 12
Table 6: Haematology Rapid Tests & Point of Care (POC) Companies - Pipeline Products by Stage of Development 13
Table 7: Haematology Rapid Tests & Point of Care (POC) - Pipeline Products by Stage of Development 14
Table 8: Atomo Diagnostics Pty Limited Pipeline Products & Ongoing Clinical Trials Overview 16
Table 9: AtomoRapid - Coagulation Monitoring - Product Status 16
Table 10: AtomoRapid - Coagulation Monitoring - Product Description 16
Table 11: BioMedomics Inc Pipeline Products & Ongoing Clinical Trials Overview 17
Table 12: Sickle SCAN - Product Status 17
Table 13: Sickle SCAN - Product Description 17
Table 14: Biosurfit, SA Pipeline Products & Ongoing Clinical Trials Overview 18
Table 15: Spinit Device - Blood Quantitation Anemia Assay - Product Status 18
Table 16: Spinit Device - Blood Quantitation Anemia Assay - Product Description 18
Table 17: Spinit Device - Thrombocytopenia Assay - Product Status 19
Table 18: Spinit Device - Thrombocytopenia Assay - Product Description 19
Table 19: Carclo Diagnostic Solutions Ltd Pipeline Products & Ongoing Clinical Trials Overview 20
Table 20: Micropoc-CAT - Haemostasis Assay - Product Status 20
Table 21: Micropoc-CAT - Haemostasis Assay - Product Description 20
Table 22: Cascade Metrix, Inc. Pipeline Products & Ongoing Clinical Trials Overview 21
Table 23: Multiple Blood Analytes Test - Product Status 21
Table 24: Multiple Blood Analytes Test - Product Description 21
Table 25: Correlia Biosystems, Inc. Pipeline Products & Ongoing Clinical Trials Overview 22
Table 26: Electrokinetic Lateral Flow Test - Product Status 22
Table 27: Electrokinetic Lateral Flow Test - Product Description 22
Table 28: EKF Diagnostics Holdings Plc Pipeline Products & Ongoing Clinical Trials Overview 23
Table 29: Point-Of-Care Test - Coagulation - Product Status 23
Table 30: Point-Of-Care Test - Coagulation - Product Description 23
Table 31: Emosis SAS Pipeline Products & Ongoing Clinical Trials Overview 24
Table 32: Diagnostic Test Kit - Heparin-Induced Thrombocytopenia - Product Status 24
Table 33: Diagnostic Test Kit - Heparin-Induced Thrombocytopenia - Product Description 24
Table 34: ET Healthcare, Inc. Pipeline Products & Ongoing Clinical Trials Overview 25
Table 35: Pylon Assay - D-Dimer - Product Status 25
Table 36: Pylon Assay - D-Dimer - Product Description 25
Table 37: genedrive plc Pipeline Products & Ongoing Clinical Trials Overview 26
Table 38: Genedrive - Factor V Leiden - Product Status 26
Table 39: Genedrive - Factor V Leiden - Product Description 26
Table 40: Helena Laboratories Corp. Pipeline Products & Ongoing Clinical Trials Overview 27
Table 41: Cascade Abrazo - APTT - Product Status 27
Table 42: Cascade Abrazo - APTT - Product Description 28
Table 43: Cascade Abrazo - c-ACT - Product Status 28
Table 44: Cascade Abrazo - c-ACT - Product Description 28
Table 45: Cascade Abrazo - c-ACT-LR - Product Status 29
Table 46: Cascade Abrazo - c-ACT-LR - Product Description 29
Table 47: Cascade Abrazo - Direct Thrombin Inhibitors - Product Status 29
Table 48: Cascade Abrazo - Direct Thrombin Inhibitors - Product Description 30
Table 49: Cascade Abrazo - Fibrinogen - Product Status 30
Table 50: Cascade Abrazo - Fibrinogen - Product Description 30
Table 51: Cascade Abrazo - Heparin Titration - Product Status 31
Table 52: Cascade Abrazo - Heparin Titration - Product Description 31
Table 53: Cascade Abrazo - LMWH - Product Status 31
Table 54: Cascade Abrazo - LMWH - Product Description 32
Table 55: Cascade Abrazo - Protamine Titration - Product Status 32
Table 56: Cascade Abrazo - Protamine Titration - Product Description 32
Table 57: Cascade Abrazo - PT-C - Product Status 33
Table 58: Cascade Abrazo - PT-C - Product Description 33
Table 59: KeenCAT Technologies Pipeline Products & Ongoing Clinical Trials Overview 34
Table 60: HematoCAT - Product Status 34
Table 61: HematoCAT - Product Description 34
Table 62: Ohio State University Pipeline Products & Ongoing Clinical Trials Overview 35
Table 63: Diagnostic Assay - Thrombotic Thrombocytopenic Purpura - Product Status 35
Table 64: Diagnostic Assay - Thrombotic Thrombocytopenic Purpura - Product Description 35
Table 65: PortaScience Inc Pipeline Products & Ongoing Clinical Trials Overview 36
Table 66: PortaWBC - Product Status 36
Table 67: PortaWBC - Product Description 36
Table 68: Sanguina LLC Pipeline Products & Ongoing Clinical Trials Overview 37
Table 69: AnemoCheck - Product Status 37
Table 70: AnemoCheck - Product Description 37
Table 71: Siemens Healthcare GmbH Pipeline Products & Ongoing Clinical Trials Overview 38
Table 72: Advia 120 Hematology System - IRF Test - Product Status 38
Table 73: Advia 120 Hematology System - IRF Test - Product Description 39
Table 74: Advia 120 Hematology System - MPC Test - Product Status 39
Table 75: Advia 120 Hematology System - MPC Test - Product Description 39
Table 76: Advia 120 Hematology System - MPM Test - Product Status 40
Table 77: Advia 120 Hematology System - MPM Test - Product Description 40
Table 78: Advia 2120 Hematology System - MPC Test - Product Status 40
Table 79: Advia 2120 Hematology System - MPC Test - Product Description 41
Table 80: Advia 2120 Hematology System - MPM Test - Product Status 41
Table 81: Advia 2120 Hematology System - MPM Test - Product Description 41
Table 82: Advia 2120i Hematology System - MPC Test - Product Status 42
Table 83: Advia 2120i Hematology System - MPC Test - Product Description 42
Table 84: Advia 2120i Hematology System - MPM Test - Product Status 42
Table 85: Advia 2120i Hematology System - MPM Test - Product Description 43
Table 86: T2 Biosystems Inc Pipeline Products & Ongoing Clinical Trials Overview 44
Table 87: T2HemoStat - Product Status 44
Table 88: T2HemoStat - Product Description 44
Table 89: T2MR Assay - Platelet Function Testing - Product Status 45
Table 90: T2MR Assay - Platelet Function Testing - Product Description 45
Table 91: The University of Melbourne Pipeline Products & Ongoing Clinical Trials Overview 46
Table 92: Thrombin Generation Assay - Product Status 46
Table 93: Thrombin Generation Assay - Product Description 46
Table 94: Universal Biosensors Inc Pipeline Products & Ongoing Clinical Trials Overview 47
Table 95: Diagnostic Assay - Coagulation - Product Status 47
Table 96: Diagnostic Assay - Coagulation - Product Description 47
Table 97: Glossary 130

1.2 List of Figures
Figure 1: Haematology Rapid Tests & Point of Care (POC) - Pipeline Products by Stage of Development 8
Figure 2: Haematology Rapid Tests & Point of Care (POC) - Pipeline Products by Segment 9
Figure 3: Haematology Rapid Tests & Point of Care (POC) - Pipeline Products by Territory 10
Figure 4: Haematology Rapid Tests & Point of Care (POC) - Pipeline Products by Regulatory Path 11
Figure 5: Haematology Rapid Tests & Point of Care (POC) - Pipeline Products by Estimated Approval Date 12
  • Immunohematology and Infectious Disease NAT Screening Market 2021: Competitive Analysis of Major Suppliers and Emerging Market Entrants
    Published: 15-Nov-2017        Price: US 2750 Onwards        Pages: 0
    This new report from VPGMarketResearch.com provides strategic assessments of major blood banking product suppliers and emerging market entrants. The report presents analyses of major current and emerging suppliers in terms of their sales, market shares, product portfolios, marketing tactics, technological know-how, new products in R&D, collaborative arrangements, and business strategies. Contains 50 pages ......
  • Hematology and Flow Cytometry Market 2021: Global Opportunities and Growth Strategies for Instrument and Reagent Suppliers
    Published: 15-Nov-2017        Price: US 34500 Onwards        Pages: 0
    Complete report $34,500.DataPack (test volumes, sales forecasts, supplier shares) $15,900.SummaryThis comprehensive seven-country report contains 700 pages, 250 tables, and is designed to help current suppliers and potential market entrants identify and evaluate business opportunities emerging in the global hematology and flow cytometry markets during the next five years.The report explores......
  • France Hematology and Flow Cytometry Market 2021: Emerging Opportunities and Growth Strategies for Instrument and Reagent Suppliers
    Published: 15-Nov-2017        Price: US 6200 Onwards        Pages: 0
    Complete report $6,200. DataPack (test volumes, sales forecasts, supplier shares) $3,900.SummaryThis comprehensive report contains 250 pages, 32 tables, and is designed to help current suppliers and potential market entrants identify and evaluate business opportunities emerging in French hematology and flow cytometry markets during the next five years.The report explores business and technological trends in ......
  • Germany Hematology and Flow Cytometry Market 2021: Emerging Opportunities and Growth Strategies for Instrument and Reagent Suppliers
    Published: 15-Nov-2017        Price: US 6200 Onwards        Pages: 0
    Complete report $6,200. DataPack (test volumes, sales forecasts, supplier shares) $3,900.SummaryThis comprehensive report contains 250 pages, 32 tables, and is designed to help current suppliers and potential market entrants identify and evaluate business opportunities emerging in German hematology and flow cytometry markets during the next five years.The report explores business and technological trends in the......
  • Italy Hematology and Flow Cytometry Market 2021: Emerging Opportunities and Growth Strategies for Instrument and Reagent Suppliers
    Published: 15-Nov-2017        Price: US 6200 Onwards        Pages: 0
    Complete report $6,200. DataPack (test volumes, sales forecasts, supplier shares) $3,900.SummaryThis comprehensive report contains 250 pages, 32 tables, and is designed to help current suppliers and potential market entrants identify and evaluate business opportunities emerging in Italian hematology and flow cytometry markets during the next five years.The report explores business and technological trends in......
  • Japan Hematology and Flow Cytometry Market 2021: Emerging Opportunities and Growth Strategies for Instrument and Reagent Suppliers
    Published: 15-Nov-2017        Price: US 8800 Onwards        Pages: 0
    Complete report $8,800. DataPack (test volumes, sales forecasts, supplier shares) $5,700.SummaryThis comprehensive report contains 250 pages, 32 tables, and is designed to help current suppliers and potential market entrants identify and evaluate business opportunities emerging in Japanese hematology and flow cytometry markets during the next five years. The report explores business and technological trends in ......
  • Spain Hematology and Flow Cytometry Market 2021: Emerging Opportunities and Growth Strategies for Instrument and Reagent Suppliers
    Published: 15-Nov-2017        Price: US 6200 Onwards        Pages: 0
    Complete report $6,200. DataPack (test volumes, sales forecasts, supplier shares) $3,900.SummaryThis comprehensive report contains 255 pages, 34 tables, and is designed to help current suppliers and potential market entrants identify and evaluate business opportunities emerging in Spanish hematology and flow cytometry markets during the next five years.The report explores business and technological trends in......
  • UK Hematology and Flow Cytometry Market 2021: Emerging Opportunities and Growth Strategies for Instrument and Reagent Suppliers
    Published: 15-Nov-2017        Price: US 6200 Onwards        Pages: 0
    Complete report $6,200. DataPack (test volumes, sales forecasts, supplier shares) $3,900.SummaryThis comprehensive report contains 250 pages, 30 tables, and is designed to help current suppliers and potential market entrants identify and evaluate business opportunities emerging in UK hematology and flow cytometry markets during the next five years.The report explores business and technological trends in the ......
  • US Hematology and Flow Cytometry Market 2021: Emerging Opportunities and Growth Strategies for Instrument and Reagent Suppliers
    Published: 15-Nov-2017        Price: US 9850 Onwards        Pages: 0
    Complete report $9,850. DataPack (test volumes, sales forecasts, supplier shares) $6,400.SummaryThis comprehensive report contains 275 pages, 36 tables, and is designed to help current suppliers and potential market entrants identify and evaluate business opportunities emerging in US hematology and flow cytometry markets during the next five years.The report explores business and technological trends in the ......
  • SERVICES
    Value for Money
    We believe in "optimum utilization of available budget and resources". While servicing our clients' (your) market research requirements, we keep the same approach in focus to help you get the best value for your $$s.
    Ever Growing Inventory
    Ranging from the smallest feasible / required data (datasheets, data facts, SWOT analysis, company profiles, etc) to full research reports that help you make decisions, our inventory is updated almost on a daily basis with the latest industry reports from domain experts that track more than 5000 niche sectors.
    One Stop Solution
    Need a custom research report on medical devices market? Require all available business intelligence on 3D printing industry? Exploring F&B sector of a particular country/region? RnRMarketResearch.com is your one-stop-solution to all market intelligence needs. We not only offer custom research and consulting services, we also "bundle" reports to meet your needs and help you fetch the data analysis you require for your business.
    Dedicated Client Engagement
    Not limited to only "finding" relevant reports for you, our client engagement team dedicates its efforts to understand your "business need" and accordingly maps available research data to help you move forward. Call "your" client engagement executive any time of your day and get your questions answered in order to make the correct business decision.
    Saving Time and Efforts
    Simply share your research requirement details with us and let us do all the hard work to find required intelligence for you. When you add up our "one stop solution" and "dedicated client engagement" services mentioned above, you obviously know the time and effort saving you do by working with us.
    Payment Flexibility
    Working with Fortune 500 organizations, we understand the importance of being flexible for payments. Share your payment terms with us and we will surely match up to them to ensure you get access to required business intelligence data without having to wait for the payment to be done.
    Post-Purchase Research Support
    Have questions after reading a report / datasheet bought through us? Not sure about the methodology used for data available in the research? Talk to us / Share your questions with us and if required, we will connect you with the analyst(s)/author(s) of the report(s) and ensure you get satisfactory answers for the same. Need more data / analysis / report(s) on the topic of your research/project? The RnRMarketResearch.com team is here for you 24X7 to support you with your post-purchase requirements. Subscription Offers & Packages (Get in touch with us for more details - sales@rnrmarketresearch.com / +1 888 391 5441 )
    • Ad Hoc
    • Pay - as - you - go / Bucket Subscriptions
    • Fixed Cost for #of reports
    • Customize / Personalize as per your needs